The Fund’s Managers Stressed Valeant’s Unusual Business Design
Saturday, December 31st, 2011Valeant Pharmaceutical drugs, the fund’s biggest holding, were built with a market price of under $7.5 billion (VRX) when Sequoia bought it within the third quarter of 2010, Bloomberg data show. The Mississauga, Ontario, drug company acquired 62 percent this season.
In the 2011 investor meeting, the fund’s managers stressed Valeant’s unusual business design, which concentrates on obtaining drugs having a proven history instead of investing cash on research and development. Additionally they recognized the firm’s ceo, J. Michael Pearson.
Goldfarb told traders that with time he’s become believing that the best executive is vital to some business’s success. “We’re betting more about the jockey and rather less around the equine,” he stated in May in the fund’s annual meeting.
Sequoia typically has much more cash compared to Litigation held through the average U.S. domestic stock fund. In the finish from the third quarter, cash symbolized 27 percent from the fund’s assets, based on data put together by Bloomberg.
Other well-known value traders, for example Seth Klarman, founding father of Baupost Group LLC, a Boston-based hedge fund, and Robert Rodriguez, the longtime manager of FPA Capital Fund and current Boss of La-based First Off-shore Experts, let cash develop once they can’t find enough attractive opportunities.
“In good marketplaces cash could be a drag, but we haven’t had many good marketplaces recently,” Serta Teed, leader of Wedgewood Traders Corporation. in Erie, Pennsylvania, stated inside a telephone interview. Teed, whose firm handles a lot more than $100 million, including shares of Sequoia, stated the fund’s cash would be a plus since it means they “aren’t afraid to consider a defensive position.